Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DXCM NASDAQ:PODD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXCMDexCom$61.63+6.6%$63.46$54.11▼$89.98$23.78B1.45.26 million shs11.13 million shsPODDInsulet$147.46-0.8%$199.93$145.59▼$354.88$10.21B1.21.64 million shs1.44 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXCMDexCom0.00%+1.68%+0.65%-11.98%-28.77%PODDInsulet0.00%-4.35%-26.81%-39.25%-54.12%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXCMDexCom$61.63+6.6%$63.46$54.11▼$89.98$23.78B1.45.26 million shs11.13 million shsPODDInsulet$147.46-0.8%$199.93$145.59▼$354.88$10.21B1.21.64 million shs1.44 million shsBeginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXCMDexCom0.00%+1.68%+0.65%-11.98%-28.77%PODDInsulet0.00%-4.35%-26.81%-39.25%-54.12%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDXCMDexCom 2.92Moderate Buy$83.2235.03% UpsidePODDInsulet 2.72Moderate Buy$257.0974.35% UpsideCurrent Analyst Ratings BreakdownLatest PODD and DXCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026PODDInsulet Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)5/12/2026PODDInsulet BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy5/11/2026DXCMDexCom BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$77.005/11/2026DXCMDexCom BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/7/2026PODDInsulet The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$237.005/7/2026PODDInsulet Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$325.00 ➝ $280.005/7/2026PODDInsulet Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$315.00 ➝ $250.005/7/2026PODDInsulet Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$330.00 ➝ $200.005/7/2026PODDInsulet BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetUnderweight$286.00 ➝ $198.005/7/2026PODDInsulet Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price Target$350.00 ➝ $250.005/7/2026PODDInsulet Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price Target$355.00 ➝ $263.00(Data available from 5/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDXCMDexCom$4.66B5.10$2.77 per share22.26$7.66 per share8.05PODDInsulet$2.71B3.77$6.32 per share23.32$18.81 per share7.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDXCMDexCom$836.30M$2.3426.3420.481.0619.31%33.33%13.19%7/29/2026 (Estimated)PODDInsulet$247.10M$4.3034.2918.431.2010.44%26.87%12.01%N/ALatest PODD and DXCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026PODDInsulet$1.19$1.42+$0.23$1.30$729.89 million$761.70 million4/30/2026Q1 2026DXCMDexCom$0.47$0.56+$0.09$0.51$1.17 billion$1.19 billion2/18/2026Q4 2025PODDInsulet$1.48$1.55+$0.07$1.44$768.31 million$783.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDXCMDexComN/AN/AN/AN/AN/APODDInsuletN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDXCMDexCom0.421.951.64PODDInsulet0.712.491.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDXCMDexCom97.75%PODDInsuletN/AInsider OwnershipCompanyInsider OwnershipDXCMDexCom0.28%PODDInsulet0.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDXCMDexCom11,000385.87 million384.79 millionOptionablePODDInsulet5,40069.26 million69.02 millionOptionablePODD and DXCM HeadlinesRecent News About These CompaniesInsulet Corporation $PODD Stock Holdings Increased by DNB Asset Management AS3 hours ago | marketbeat.comWhy Goldman Sachs Trimmed Insulet Corporation (PODD) Price Target Despite Strong Q1 ResultsMay 15 at 8:11 AM | insidermonkey.comInsulet (PODD) price target decreased by 21.96% to 270.07May 14 at 7:44 PM | msn.com5 Most Oversold Large Cap Stocks to BuyMay 14 at 2:31 PM | insidermonkey.comWhy Insulet (PODD) Stock Is Trading Up TodayMay 13, 2026 | theglobeandmail.comThere May Be Reason For Hope In Insulet's (NASDAQ:PODD) Disappointing EarningsMay 13, 2026 | finance.yahoo.comInsulet Corporation (PODD) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comInsulet: An Opportune Time To Get InvolvedMay 13, 2026 | seekingalpha.comHere's Why Insulet (PODD) is a Strong Growth StockMay 12, 2026 | zacks.comInsulet (NASDAQ:PODD) Shares Unloaded Sen. Tina SmithMay 12, 2026 | marketbeat.comSen. Tina Smith Sells Insulet Corporation (NASDAQ:PODD) StockMay 12, 2026 | marketbeat.comWhy Insulet (PODD) is a Top Value Stock for the Long-TermMay 11, 2026 | zacks.comInsulet establishes Middle East regional headquarters in Riyadh, marking a strategic milestone in the KingdomMay 11, 2026 | zawya.comZKatamaran Capital LLP Takes Position in Insulet Corporation $PODDMay 11, 2026 | marketbeat.comC WorldWide Group Holding A S Sells 10,000 Shares of Insulet Corporation $PODDMay 11, 2026 | marketbeat.comJefferies Financial Group Cuts Insulet (NASDAQ:PODD) Price Target to $360.00May 10, 2026 | americanbankingnews.comCitigroup Cuts Insulet (NASDAQ:PODD) Price Target to $175.00May 10, 2026 | americanbankingnews.comStifel Nicolaus Cuts Insulet (NASDAQ:PODD) Price Target to $250.00May 10, 2026 | americanbankingnews.comCanaccord Genuity Group Cuts Insulet (NASDAQ:PODD) Price Target to $249.00May 10, 2026 | americanbankingnews.comLeerink Partners Cuts Insulet (NASDAQ:PODD) Price Target to $247.00May 10, 2026 | americanbankingnews.comRobert W. Baird Cuts Insulet (NASDAQ:PODD) Price Target to $248.00May 10, 2026 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026AMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 20263 Reasons Analysts Love DexComBy Nathan Reiff | May 5, 2026PODD and DXCM Company DescriptionsDexCom NASDAQ:DXCM$61.63 +3.81 (+6.59%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$61.61 -0.02 (-0.03%) As of 05/15/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.Insulet NASDAQ:PODD$147.46 -1.22 (-0.82%) Closing price 05/15/2026 04:00 PM EasternExtended Trading$147.38 -0.08 (-0.05%) As of 05/15/2026 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Peloton Stock Gives Back Gains After Upbeat Earnings Report MarketBeat Week in Review – 05/11 - 05/15 Datavalut Gains Traction: 5 Reasons to Sell Now TMC Stock: Why This Pre-Revenue Miner Is Worth Watching Alphabet's Googlebook Brings Gemini AI to PC Hardware Viking Sails to All-Time Highs—Fundamentals Signal More to Come YETI Rallies After Earnings Beat and Raised Outlook Aeluma's Post-Earnings Dip Creates a Buying Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
